| Title: | Management of sleep/wake cycles improves cognitive function in a transgenic mouse model of Huntington's disease |
| Address: | "Department of Pharmacology, University of Cambridge, Cambridge, UK" |
| DOI: | 10.1016/j.brainres.2009.03.072 |
| ISSN/ISBN: | 1872-6240 (Electronic) 0006-8993 (Linking) |
| Abstract: | "Normally, mice sleep during the day and are active at night. In Huntington's disease mice (R6/2 line) this circadian pattern disintegrates progressively over the course of their illness. Cognitive decline and apathy in R6/2 mice can be improved with sleeping drugs, suggesting that sleep disruption contributes to their neurological decline. We wondered if wakefulness was equally important. Here, we used two drugs to manage sleep/wake cycles in R6/2 mice, Alprazolam (to put them to sleep) and Modafinil (to wake them up). We found that both drugs improved cognitive function and apathy, but had a stronger effect when used in combination. Remarkably, beneficial effects on cognitive performance were also seen in vehicle-treated cage-mates of Alprazolam/Modafinil-treated mice, suggesting that behavioral intervention to regularize sleep/wake activity might be therapeutically useful. We suggest that focused management of sleep and wakefulness will slow the progression of cognitive decline and apathy in neurological conditions where sleep is disordered" |
| Keywords: | Affect/drug effects Alprazolam/administration & dosage Animals Benzhydryl Compounds/administration & dosage Body Weight/drug effects Central Nervous System Stimulants/administration & dosage Cognition/*drug effects Cognition Disorders/complications/drug t; |
| Notes: | "MedlinePallier, Patrick N Morton, A Jennifer eng Research Support, Non-U.S. Gov't Netherlands 2009/05/20 Brain Res. 2009 Jul 7; 1279:90-8. doi: 10.1016/j.brainres.2009.03.072. Epub 2009 May 18" |
